Results 131 to 140 of about 13,611 (195)

Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG). [PDF]

Psychopharmacology (Berl), 2017
Hicks C, Gregg RA, Nayak SU, Cannella LA, Schena GJ, Tallarida CS, Reitz AB, Smith GR, Rawls SM.   +8 more
europepmc   +1 more source

δ-Thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors. [PDF]

J Med Chem, 2014
Ferraris DV, Majer P, Ni C, Slusher CE, Rais R, Wu Y, Wozniak KM, Alt J, Rojas C, Slusher BS, Tsukamoto T.   +10 more
europepmc   +1 more source

Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II. [PDF]

FEBS J, 2014
Navrátil M, Ptáček J, Šácha P, Starková J, Lubkowski J, Bařinka C, Konvalinka J.   +6 more
europepmc   +1 more source

Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. [PDF]

Curr Med Chem, 2012
Bařinka C, Rojas C, Slusher B, Pomper M.   +3 more
europepmc   +1 more source

Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. [PDF]

Proc Natl Acad Sci U S A, 2012
Rahn KA, Watkins CC, Alt J, Rais R, Stathis M, Grishkan I, Crainiceau CM, Pomper MG, Rojas C, Pletnikov MV, Calabresi PA, Brandt J, Barker PB, Slusher BS, Kaplin AI.   +14 more
europepmc   +1 more source

Metabolism and function of Ca2+ in secretory cells [PDF]

, 1988
Gratzl, Manfred, Thorn, Niels A.
core  

Development of a high-throughput fluorescence polarization assay to identify novel ligands of glutamate carboxypeptidase II. [PDF]

J Biomol Screen, 2012
Alquicer G, Sedlák D, Byun Y, Pavlícek J, Stathis M, Rojas C, Slusher B, Pomper MG, Bartunek P, Barinka C.   +9 more
europepmc   +1 more source

Prostate‑specific membrane antigen: Molecular functions and emerging roles as a therapeutic target (Review). [PDF]

Mol Med Rep
Watanabe R, Sakaue T, Miura N, Kikugawa T, Saika T.   +4 more
europepmc   +1 more source

Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo. [PDF]

Drug Metab Dispos, 2012
Rais R, Hoover R, Wozniak K, Rudek MA, Tsukamoto T, Alt J, Rojas C, Slusher BS.   +7 more
europepmc   +1 more source

Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism. [PDF]

J Pharmacol Exp Ther, 2013
Vornov JJ, Wozniak KM, Wu Y, Rojas C, Rais R, Slusher BS.   +5 more
europepmc   +1 more source